| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 25.05.
| Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics | | 66 | Business Wire |
| Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) (Spectrum) and Allos
Therapeutics, Inc. (NasdaqGS: ALTH) (Allos) today announced that
Spectrum has provided an additional...
Mehr lesen zu:
Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics | |
| 17.05.
| Spectrum Pharmaceuticals Commences Phase 2 Study of ZEVALIN in Combination with the Redox Modulating Agent Motexafin Gadolinium | | 1 | Benzinga.com |
| 17.05.
| Spectrum Pharmaceuticals Commences Phase 2 Study of ZEVALIN® in Combination with the Redox Modulating Agent Motexafin Gadolinium (MGd) | | 33 | Business Wire |
| Previous Phase 1/2 Combination Study Resulted in Overall Response
Rate of 86%, Complete Response Rate of 64% in Rituximab-Refractory
Patients
MGd...
Mehr lesen zu:
Spectrum Pharmaceuticals Commences Phase 2 Study of ZEVALIN® in Combination with the Redox Modulating Agent Motexafin Gadolinium (MGd) | |
| 14.05.
| Spectrum Pharmaceuticals Earnings Review: 18 Days after Announcement Shares Up 9.3% | | 4 | SmarTrend |
| 10.05.
| Spectrum Pharmaceuticals and Allos Therapeutics Announce Extension of Previously Announced Tender Offer For Shares of Allos Therapeutics | | 36 | Business Wire |
| Federal Trade Commission Has Requested additional Information
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) (Spectrum) and Allos
Therapeutics, Inc....
Mehr lesen zu:
Spectrum Pharmaceuticals and Allos Therapeutics Announce Extension of Previously Announced Tender Offer For Shares of Allos Therapeutics | |
| 08.05.
| Spectrum Pharmaceuticals Crosses Below its 10-day MA | | 1 | SmarTrend |
| 08.05.
| Spectrum Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care Conference | | 33 | Business Wire |
| Corporate Overview to be Presented on Tuesday, May 15th
at 8:00am Pacific Time
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology...
Mehr lesen zu:
Spectrum Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care Conference | |
| 04.05.
| Equity Research on Spectrum Pharmaceuticals Inc. and Amgen Inc. - Biotechnology Companies Releasing Strong Earnings | | 46 | MarketWire |
| NEW YORK, NY -- (Marketwire) -- 05/04/12 -- www.shinesrooms.com has a handpicked team of market professionals with over 100 years of combined investing experience. Today they are providing members...
Mehr lesen zu:
Equity Research on Spectrum Pharmaceuticals Inc. and Amgen Inc. - Biotechnology Companies Releasing Strong Earnings | |
| 01.05.
| Spectrum Pharmaceuticals to Present at the Deutsche Bank 37th Annual Health Care Conference | | 39 | Business Wire |
| Corporate Overview to be Presented on Tuesday, May 8th
at 4:10pm Eastern Time
Spectrum Pharmaceuticals (NasdaqGS:SPPI), a biotechnology...
Mehr lesen zu:
Spectrum Pharmaceuticals to Present at the Deutsche Bank 37th Annual Health Care Conference | |
| 26.04.
| Spectrum Pharmaceuticals Reports Record Revenues and Profits for First Quarter of 2012 | | 40 | Business Wire |
| Financial Highlights of the Quarter
EPS of $0.71 Per Diluted Share Compared to $0.23 Per Diluted
Share in the Same Quarter Last Year.
Total...
Mehr lesen zu:
Spectrum Pharmaceuticals Reports Record Revenues and Profits for First Quarter of 2012 | |
| 24.04.
| Spectrum Pharmaceuticals Shares Down 25.1% Since SmarTrend's Sell Call | | 2 | SmarTrend |
| 23.04.
| Spectrum Pharmaceuticals Expands Manufacturing Capacity and Builds Inventory Reserves for FUSILEV® | | 43 | Business Wire |
| FUSILEV Was Approved by the FDA in April of 2011 for Patients with
Advanced Metastatic Colorectal Cancer.
Spectrum Embarked on a Long-term Manufacturing...
Mehr lesen zu:
Spectrum Pharmaceuticals Expands Manufacturing Capacity and Builds Inventory Reserves for FUSILEV® | |
| 19.04.
| Spectrum Pharmaceuticals Bullish Moving Average Crossover Alert | | 2 | SmarTrend |
| 19.04.
| Spectrum Pharmaceuticals to Be Added to the S&P SmallCap 600 Index | | 43 | Business Wire |
| Meets Specific Investment and Financial Strength Criteria
Spectrum Pharmaceuticals (Nasdaq: SPPI), a biotechnology company with
fully...
Mehr lesen zu:
Spectrum Pharmaceuticals to Be Added to the S&P SmallCap 600 Index | |
| 17.04.
| Spectrum Pharmaceuticals Announces First Quarter 2012 Financial Results Teleconference and Webcast | | 40 | Business Wire |
| Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with
fully integrated commercial and drug development operations with a
primary focus in hematology...
Mehr lesen zu:
Spectrum Pharmaceuticals Announces First Quarter 2012 Financial Results Teleconference and Webcast | |
| 17.04.
| Shares of Spectrum Pharmaceuticals Rank the Lowest in Terms of Debt-to-Capital Ratio in the Biotechnology Industry | | 1 | SmarTrend |
| 16.04.
| Spectrum Pharmaceuticals Commences Tender Offer for All Outstanding Shares of Allos Therapeutics at $1.82/Share for Each Allos Stock | | 1 | Benzinga.com |
| 16.04.
| Spectrum Pharmaceuticals Commences Tender Offer for All Outstanding Shares of Allos Therapeutics | | 64 | Business Wire |
| Spectrum Pharmaceuticals (NASDAQ:SPPI) today announced that it commenced
on Friday, April 13, 2012 a cash tender offer to purchase all of the
outstanding shares of common...
Mehr lesen zu:
Spectrum Pharmaceuticals Commences Tender Offer for All Outstanding Shares of Allos Therapeutics | |
| 10.04.
| Shares of Spectrum Pharmaceuticals Under Pressure, Down 3.9% | | 2 | SmarTrend |
| 10.04.
| Spectrum Pharmaceuticals Has Returned 27.2% Since SmarTrend Recommendation | | - | SmarTrend |
